Lapatinib Completed Phase 2 Trials for Neoplasms, Breast Treatment

IndicationsStatusPurposePhase
CompletedTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT00356811Lapatinib Combined With Paclitaxel For Patients With First-Line ErbB2-Amplified Metastatic Breast Cancer
NCT00089999Lapatinib In Chemotherapy-Naive Or Metastatic Breast Cancer
NCT00429299Neoadjuvant Study With Chemotherapy, Lapatinib And Trastuzumab In Breast Cancer
NCT00347919Pazopanib Plus Lapatinib Compared To Lapatinib Alone In Subjects With Advanced Or Metastatic Breast Cancer
NCT00524303Lapatinib +/- Trastuzumab In Addition To Standard Neoadjuvant Breast Cancer Therapy.
NCT00105950Study Of Lapatinib In Patients With Relapsed Or Refractory Inflammatory Breast Cancer
NCT00558103Pazopanib Plus Lapatinib Compared To Lapatinib Alone In Subjects With Inflammatory Breast Cancer
NCT00422903Letrozole In Combination With Lapatinib In Neoadjuvant Treatment Of Early Breast Cancer
NCT00062686GW572016 For Treatment Of Refractory Metastatic Breast Cancer
NCT00320411GW572016 In Patients With ErbB2 Over - Expressing Advanced Or Metastatic Breast Cancer
NCT00709761Phase II Lapatinib Plus Nab-Paclitaxel As First And Second Line Therapy In her2+ MBC
NCT008262676 Weeks Treatment of Locally Advanced Breast Cancer With BIBW 2992 (Afatinib) or Lapatinib or Trastuzumab
NCT00263588Lapatinib for Brain Metastases In ErbB2-Positive Breast Cancer